Davenport & Co
ITCI icon

Davenport & Co’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Davenport & Co’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,350
Closed -$234K – 616
2015
Q4 		$234K Buy
+4,350
New +$219K ﹤0.01% 501

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock Advisors
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Davenport & Co's ITCI Position: Q1 2016 in Review

Davenport & Co sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2016, closing a stake of 4,350 shares — an estimated $234K sold.

Davenport & Co first reported a position in ITCI in Q4 2015 and held it in 1 quarter. The position peaked at $234K in Q4 2015. 127 funds tracked by Wall St. Rank hold ITCI as of Q1 2016.

  • Davenport & Co reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2016 after selling out during the quarter.
  • Davenport & Co sold 4,350 Intra-Cellular Therapies Inc. shares in Q1 2016, an estimated $234K.
  • Davenport & Co first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 1 quarter.
  • Davenport & Co's Intra-Cellular Therapies Inc. position peaked at $234K in Q4 2015.
  • 127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2016.

Based on Davenport & Co's 13F filing for Q1 2016, filed 25 Apr 2016.